Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

Authors :: Daniel J. DeAngelo
Vinod A. Pullarkat
Miguel Piris-Villaespesa
Tracy I. George
Jay L. Patel
Celalettin Ustun
Prithviraj Bose
Mark L Heaney
Jessica Sachs
Lei Sun
Amanda Pilla
Benjamin Exter
Hina A. Jolin
Tsewang Tashi
Source :: Blood. 140:1512-1513
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Tools